Table 1.

Demographic and clinical characteristics of participants

All Participants (n=836,060)Baseline eGFR (ml/min per 1.73 m2)
15–59.9 (n=47,092)60–89.9 (n=351,849)≥90 (n=437,119)
Agea (yr)49.4 (14.8)70.5 (11.5)55.6 (12.9)42.1 (11.8)
LDL-Ca (mmol/L)3.1 (0.9)3.1 (0.9)3.2 (0.9)3.0 (0.9)
LDL-C (mmol/L)
Aboriginal status1112
Socioeconomic status
 Social assistance2223
eGFR (ml/min per 1.73 m2)b91 (78, 103)53 (45, 57)79 (72, 85)102 (96, 110)
Charlson comorbidities
 Chronic lung disease12171211
 Metastatic solid tumor0100
 Myocardial infarction2721
 Mild liver disease1111
 Moderate/severe liver disease0000
 Peptic ulcer disease2322
 Peripheral vascular disease1510
 Rheumatic disease1211
Medication usec
 ACE inhibitor or ARB23462310
 Fibrate or ezetimibe2621
  • Data expressed as percent except where noted. Totals do not always add to 100% because of rounding. Proteinuria defined as none (ACR<30 mg/g or urine dipstick negative), mild (ACR=30–300 mg/g or urine dipstick trace or 1+), or heavy (ACR>300 mg/g or urine dipstick≥2+). Low socioeconomic status was defined by annual family income<$39,250 CAD, and receiving social assistance was based on government of Alberta health care insurance records. CVD, cerebrovascular disease; CHF, congestive heart failure; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.

  • a Mean (SD).

  • b Median (interquartile range).

  • c Among the 273,540 individuals with data available on medication use, 40,611 individuals had eGFR=15–59.9, 155,315 individuals had eGFR=60–89.9, and 77,614 individuals had eGFR≥90 ml/min per 1.73 m2.